12/4/2023 0 Comments Breath of orbis priority 2021![]() ![]() This rate was higher than the 37% minimum meaningful rate study assumption (P=20%) of any grade in patients receiving venetoclax in the combination studies with obinutuzumab or rituximab were neutropenia, diarrhoea, and upper respiratory tract infection.? In the monotherapy studies, the most common adverse reactions were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection. The ibrutinib and venetoclax cohort met its primary endpoint of complete response (CR) rate of 56% (95% CI 48-64) among patients without del(17p), 70 years old or younger and with 27.9 months of follow up. NORTH CHICAGO, Ill., J/PRNewswire/ - AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE ( PCYC-1142) study investigating IMBRUVICA ® (ibrutinib) in combination with VENCLEXTA ®/VENCLYXTO ® (venetoclax), an all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination, for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) during an oral presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting ( Abstract #7501).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |